Novo Nordisk (NVO) high-dose Wegovy shows 27.7% weight loss
Published on Β· Source: cnbc.com
AI Summary
Summarized by AI from the source belowNovo Nordisk (NVO) announced that patients taking the high-dose 7.2-milligram version of Wegovy lost an average of 27.7% of their weight over 72 weeks in a recent trial. This data was presented at the European Congress on Obesity and could assist Novo in enhancing its competitive position against Eli Lilly's (LLY) Zepbound, which has shown weight loss of over 20%. The previous highest dose of Wegovy (2.4 mg) resulted in a 17% average weight loss. Approximately 25% of patients in the higher dose trial experienced early treatment response, achieving significant weight loss early in the treatment cycle.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Pfizer (PFE) Stock Down Over 50% from 2021 High Amid Challenges
- Eli Lilly (LLY) Reports 56% Revenue Growth, Raises 2026 Outlook
- Premarket Stocks: Meta, Eli Lilly, Caterpillar and Amazon Update
- Eli Lilly (LLY) Reports Q1 Earnings, Raises 2026 Revenue Outlook by $2B
- Eli Lilly (LLY) Reports $12.9 Billion in GLP-1 Drug Sales
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
